Skip to main content

Treatment with Manganese Porphyrin, MnTnBuOE-2-PyP5+, Suppressed the Activation of Macrophages in a Mouse Intracerebral Hemorrhage.

Publication ,  Journal Article
Zhang, S; Cao, J; Spasojevic, I; Treggiari, M; Sheng, H
Published in: Pharmaceuticals (Basel)
April 8, 2025

Background: Manganese porphyrin, MnTnBuOE-2-PyP5+ (BMX-001), improves neurologic deficits in experimental ischemic stroke and has the potential to serve as an adjunct with thrombolysis or thrombectomy in stroke patients. In 10-30% of stroke patients following thrombolysis, the hemorrhagic transformation, associated with iron release, occurs. This study aimed to examine the neurologic outcome following the BMX-001 treatment in a mouse intracerebral hemorrhage (ICH) model with relevance to prospective ischemic stroke clinical trials. Methods: Twenty C57Bl6 mice were randomly assigned to groups after surgery and received vehicle or BMX-001 treatment immediately following stereotaxic left striatum collagenase injection. Post-ICH body weight, the Corner test, neurological deficit score, and Rotarod test were examined. Six sham surgery mice serve as a control group. At 72 h, the brain histological evaluation was performed, including hemorrhage size, Prussian blue staining, and the activation of macrophages. Data were collected by a researcher who was blind to groups. Results: No significant difference in body weight, neurological deficits, and hemorrhage size was found between groups. However, BMX-001 reduced the number of macrophages in the hemorrhagic area (48 ± 10 in vehicle, 33 ± 8 in BMX-001, p = 0.008) and the number of cells stained with Prussian blue-an indicator of iron released during hemorrhage (65 ± 22 in vehicle and 41 ± 15 in BMX-001, p = 0.027). Conclusions: The results support the safe use of BMX-001 in stroke patients in combination with thrombolysis or thrombectomy and, moreover, indicate the beneficial anti-inflammatory effect of BMX-001, alike to that previously reported in stroke studies of analogous, similarly redox-active, Mn porphyrins.

Duke Scholars

Published In

Pharmaceuticals (Basel)

DOI

ISSN

1424-8247

Publication Date

April 8, 2025

Volume

18

Issue

4

Location

Switzerland

Related Subject Headings

  • 3214 Pharmacology and pharmaceutical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Zhang, S., Cao, J., Spasojevic, I., Treggiari, M., & Sheng, H. (2025). Treatment with Manganese Porphyrin, MnTnBuOE-2-PyP5+, Suppressed the Activation of Macrophages in a Mouse Intracerebral Hemorrhage. Pharmaceuticals (Basel), 18(4). https://doi.org/10.3390/ph18040547
Zhang, Shasha, Jie Cao, Ivan Spasojevic, Miriam Treggiari, and Huaxin Sheng. “Treatment with Manganese Porphyrin, MnTnBuOE-2-PyP5+, Suppressed the Activation of Macrophages in a Mouse Intracerebral Hemorrhage.Pharmaceuticals (Basel) 18, no. 4 (April 8, 2025). https://doi.org/10.3390/ph18040547.
Zhang S, Cao J, Spasojevic I, Treggiari M, Sheng H. Treatment with Manganese Porphyrin, MnTnBuOE-2-PyP5+, Suppressed the Activation of Macrophages in a Mouse Intracerebral Hemorrhage. Pharmaceuticals (Basel). 2025 Apr 8;18(4).
Zhang, Shasha, et al. “Treatment with Manganese Porphyrin, MnTnBuOE-2-PyP5+, Suppressed the Activation of Macrophages in a Mouse Intracerebral Hemorrhage.Pharmaceuticals (Basel), vol. 18, no. 4, Apr. 2025. Pubmed, doi:10.3390/ph18040547.
Zhang S, Cao J, Spasojevic I, Treggiari M, Sheng H. Treatment with Manganese Porphyrin, MnTnBuOE-2-PyP5+, Suppressed the Activation of Macrophages in a Mouse Intracerebral Hemorrhage. Pharmaceuticals (Basel). 2025 Apr 8;18(4).

Published In

Pharmaceuticals (Basel)

DOI

ISSN

1424-8247

Publication Date

April 8, 2025

Volume

18

Issue

4

Location

Switzerland

Related Subject Headings

  • 3214 Pharmacology and pharmaceutical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences